Finasteride, honestly: how it works and what the side effect numbers really show

Male pattern hair loss — formally called androgenetic alopecia — is driven primarily by a hormone called dihydrotestosterone, or DHT. DHT is a more potent metabolite of testosterone, produced by an enzyme called 5-alpha reductase. The enzyme exists in two main forms: type I (found mostly in skin and sebaceous glands) and type II (found in hair follicles, the prostate, and certain other tissues).

In genetically susceptible men, DHT binds to androgen receptors in scalp hair follicles and gradually shrinks them — a process called follicular miniaturization. Each successive hair cycle, the affected follicles produce thinner, shorter, less pigmented hairs. Eventually they may stop producing visible hair entirely. The pattern of which follicles are susceptible is genetic, which is why androgenetic alopecia tends to follow predictable receding-hairline-and-crown patterns.

Finasteride is a 5-alpha reductase type II inhibitor. By blocking the enzyme, it reduces circulating DHT levels by roughly 70% (and scalp DHT levels by even more) without significantly reducing testosterone. Less DHT means less binding to follicular androgen receptors, which means less miniaturization, which means follicles can recover at least partially.

The thing finasteride cannot do is regrow hair from follicles that have already stopped producing entirely. Once a follicle has been miniaturized to the point of dormancy, finasteride may not be able to wake it back up. The medication is much more effective at preventing further loss than at reversing severe loss — which is why starting earlier produces better outcomes than starting late.

Finasteride was originally developed by Merck in the 1980s as a treatment for benign prostatic hyperplasia (enlarged prostate). The 5 mg version (Proscar) was approved in 1992. Researchers noticed during the prostate trials that men taking finasteride were also experiencing reduced rates of hair loss and, in some cases, hair regrowth.

Merck then ran trials of a much lower dose (1 mg daily) specifically for hair loss and got FDA approval for that indication in 1997, marketed as Propecia. The pivotal five-year studies enrolled men with mild to moderate androgenetic alopecia, randomized them to finasteride 1 mg or placebo, and tracked hair counts and standardized photographs over time.

The results were definitive enough to make finasteride first-line oral therapy for male pattern hair loss for the next quarter century. Generic finasteride became available in 2013 and is now inexpensive and widely accessible.

The drug has held its position because the data is consistent and because nothing meaningfully better has emerged. Newer options like topical finasteride and oral dutasteride (a stronger 5-alpha reductase inhibitor that targets both type I and type II) have a role in specific cases, but oral finasteride 1 mg remains the standard reference treatment.

The most-cited finasteride data comes from the original five-year Merck studies. Across the placebo-controlled and extension phases, about 90% of men taking finasteride 1 mg daily either maintained their existing hair or showed some regrowth, compared with about 25% of men on placebo (the rest continued to lose). About 65% of men on finasteride showed measurable regrowth in standardized hair counts at the vertex (the crown), and a smaller proportion showed regrowth at the front of the scalp.

Importantly, the placebo group continued to lose hair steadily over the same period. The trials made it clear that "doing nothing" is not a stable option for androgenetic alopecia — it is a slow, progressive condition, and untreated men keep losing.

The benefit of finasteride plateaus around 12 to 24 months and is then maintained for as long as the medication is taken. Long-term extension studies have followed men for 10+ years on continuous finasteride and found ongoing maintenance of effect. The counterfactual — what those men would have looked like without treatment — is the comparison that matters, and the gap between treated and untreated grows over time.

A reasonable expectation for a man in his 20s or 30s starting finasteride: most likely, your hair loss will halt or substantially slow within the first year. Some thickening and modest regrowth at the crown is common in the first 12–18 months. Dramatic regrowth at the hairline is less common — but maintaining what you have is itself a meaningful win.

Finasteride’s side effect profile is the most discussed part of the medication and also the part that is most often distorted online. Here is what the data actually shows.

In the original randomized trials, sexual side effects (lower libido, ED, reduced ejaculate volume) were reported by roughly 1.3–3.8% of men on finasteride 1 mg, compared with about 0.7–2.3% of men on placebo. The absolute increase attributable to finasteride was on the order of 1–2 percentage points. Most reported events were mild and resolved either with continued use or after stopping the medication.

In real-world practice, the rates of reported side effects vary widely depending on how patients are counseled. The "nocebo effect" — where patients who are told to expect side effects then experience them — is well-documented in finasteride studies. One famous trial randomized men to either be told "this medication may cause sexual side effects" or to be told nothing about side effects; the warned group reported sexual side effects at three times the rate of the unwarned group, despite getting the same drug. This does not mean side effects are not real — it means the human brain is part of the picture in a way that is hard to disentangle from the drug effect.

Persistent post-finasteride syndrome — symptoms that continue after stopping the medication — is rare and not well-characterized in the literature. There are credible patient reports, there is no clean prospective data, and there is enough signal that thoughtful clinicians take it seriously without being able to give patients a precise risk number. The honest framing is: the risk exists, the risk is uncommon, and any man considering finasteride should be told about it explicitly.

Other reported side effects include breast tenderness or enlargement (rare), mood changes including depression (uncommon, debated in the literature), and very rarely, more severe cognitive or mood symptoms that some patients have reported as persistent.

Topical finasteride is a newer option that has become much more widely prescribed in the last several years. The active ingredient is the same, but it is formulated as a solution applied directly to the scalp, with the goal of producing high local DHT inhibition while minimizing systemic absorption.

Trial data on topical finasteride is more limited than the oral data, but the studies that exist suggest comparable efficacy at maintaining and modestly regrowing hair, with substantially lower serum DHT reduction than oral dosing produces. The hypothesis — that lower systemic absorption means lower rates of sexual side effects — is reasonable, but the trial sample sizes are too small to definitively confirm or rule out the difference.

In practice, topical finasteride has become a popular middle-ground option for men who want the benefit of finasteride but are worried about systemic side effects. Some men start with topical and switch to oral if topical alone is not enough. Some men who experienced side effects on oral finasteride try topical instead with better tolerance.

The trade-offs: topical formulations can be sticky, require consistent daily application, and may be more expensive than generic oral finasteride. They also require a compounding pharmacy in many cases, which adds a logistics layer.

Finasteride is approved for men 18 and older with male pattern hair loss. Younger men experiencing genuine androgenetic alopecia may also be appropriate candidates with informed consent — starting earlier in the disease course produces better outcomes.

It is contraindicated in women who are pregnant or could become pregnant — finasteride can cause birth defects in male fetuses, and the medication should never be handled (let alone taken) by pregnant women. The same caution applies to topical finasteride, which can be transferred via skin contact.

It is generally not recommended for men actively trying to conceive a child, because some studies suggest a small effect on sperm parameters in some users. Men planning to conceive may choose to discontinue temporarily, switch to topical, or accept the small risk after counseling.

Men with a history of major depression should discuss the medication carefully with a clinician — there is debated but not negligible signal that finasteride may worsen mood symptoms in some users.

Men who place high value on absolute side effect avoidance — and for whom hair loss is a secondary concern — may reasonably decide that the risk-benefit math does not favor finasteride for them. There is no universally right answer; this is a personal decision that should be made with full information.

A reasonable timeline for someone starting finasteride: months 1–3 are usually invisible — the medication is working, but the effect on visible hair lags behind. Some men experience a temporary increase in shedding in the first few months as the hair cycle adjusts; this is normal and not a sign that the medication is failing.

Months 6–12 are usually when the slowdown of further loss becomes visible. Compared to where you would have been without the medication, you have less new visible loss. Some men also notice modest thickening or regrowth at the crown.

Months 12–24 are typically when the maximum benefit shows up. After 24 months, the picture stabilizes — you continue to maintain hair as long as you keep taking the medication.

If you stop finasteride, the protective effect fades. DHT levels return to baseline within weeks. The hair you preserved over months or years of treatment will, over the following 12 months or so, regress back toward where it would have been without treatment. This is why finasteride is appropriately framed as a long-term commitment rather than a temporary intervention. Stopping is reasonable in some circumstances — fertility planning, side effects, personal preference — but the trade-off should be understood going in.

How quickly will I see results? Most users see the slowdown of further loss within 6 months and any visible regrowth within 9 to 12 months. Months 1 to 3 are usually invisible. If you are six weeks in and looking in the mirror twice a day for changes, you are setting yourself up for disappointment — try to take a baseline photo at month zero and another at month six, and let the comparison do the work.

Can I take less than 1 mg per day? Some studies have looked at lower doses (0.5 mg or even 0.25 mg) and found meaningful effect, though the standard dose with the most data is 1 mg daily. Some men split a 1 mg tablet to take half a dose, especially during the early adjustment period. The data on lower doses is real but less robust than for the standard dose.

What happens if I take it inconsistently? Inconsistent dosing reduces effectiveness because DHT levels rebound between missed doses. The medication’s benefit is built on sustained DHT suppression, not occasional pulses of suppression. Once-daily dosing taken at roughly the same time each day works best.

Will it interact with other medications? Finasteride has few significant drug interactions. It does not affect oral contraceptives in women (though women of childbearing potential should not take or handle finasteride at all). Patients on other 5-alpha reductase inhibitors (like dutasteride for prostate enlargement) should not stack finasteride on top.

Is dutasteride a better option? Dutasteride is a stronger 5-alpha reductase inhibitor that targets both type I and type II isoenzymes (finasteride only blocks type II). It produces greater DHT suppression and may produce somewhat better hair outcomes in head-to-head trials. It is FDA-approved in the U.S. for prostate enlargement, not for hair loss, and is prescribed off-label for the latter. Side effect profile is broadly similar but the longer half-life of dutasteride means any side effects take longer to clear after stopping.